

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

EPAS ID: PAT7795896

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
GANYMED PHARMACEUTICALS GMBH	09/26/2018
RECEIVING PARTY DATA	
Name:	ASTELLAS PHARMA INC.
Street Address:	5-1, NIHONBASHI-HONCHO 2-CHOME, CHUO-KU
City:	TOKYO
State/Country:	JAPAN
Postal Code:	103-8411
PROPERTY NUMBERS Total: 1	
Property Type	Number
Application Number:	17066232
CORRESPONDENCE DATA	
Fax Number:	
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Phone:	3122698000
Email:	koleary@nge.com, ipusmail@nge.com
Correspondent Name:	NEAL, GERBER & EISENBERG LLP
Address Line 1:	TWO NORTH LASALLE STREET
Address Line 2:	SUITE 1700
Address Line 4:	CHICAGO, ILLINOIS 60602
ATTORNEY DOCKET NUMBER:	026156-8032
NAME OF SUBMITTER:	KEVIN A. O'CONNOR
SIGNATURE:	/Kevin A. O'Connor/
DATE SIGNED:	02/14/2023
Total Attachments: 2	
source=026156-8032 Assignment 6#page2.tif	
source=026156-8032 Assignment 6#page3.tif	

ASSIGNMENT

WHEREAS, Ganymed Pharmaceuticals GmbH, a German Corporation, with offices at An der Goldgrube 12, 55131 Mainz, Germany (Assignor) owns all right title and interest in and to the following Patent applications listed in the Schedule A attached hereto.

AND, WHEREAS, Astellas Pharma Inc., a Japanese Corporation, with offices at 5-1, Nihonbashi-Honcho 2-Chome, Chuo-ku, Tokyo 103-8411, Japan (Assignee), is desirous of acquiring the entire right, title and interest in and to said improvements in and to said patent applications, all patent rights therefor, and the right to sue for past infringement;

Now, therefore, for good and valuable consideration, the receipt whereof is acknowledged, Assignor sells, assigns and transfers unto Assignee the entire right, title and interest in and to the said Patent applications; the same to be held and enjoyed by the Assignee for its own use and behoof, and for its legal representatives and assigns, to the full end of the term for which said Patent application(s) is(are) granted, as fully and entirely as the same would have been held by Assignor had this assignment and sale not been made.

Ganymed Pharmaceuticals GmbH

Date: September 26, 2018

By:  _____

Name: Kevin D. Miles

Title: General Manager

**SCHEDULE A
PATENT LIST**

Country	Application Date	Application No.	title
US	18.02.2014	15/684168	COMBINATION THERAPY INVOLVING ANTIBODIES AGAINST CLAUDIN 18.2 FOR TREATMENT OF CANCER
US	21.05.2013	15/973116	Combination Therapy Involving Antibodies Against Claudin 18.2 For Treatment of Cancer
US	21.05.2013	15/909577	Synopsis zu IMAB362 Kombinaltonsstudie "Gastchemo"
US	06.05.2013	15/227565	Antibodies Against Claudin 18.2 Useful in Cancer Diagnosis
US	13.04.2016	15/565848	Drug Conjugates Comprising Antibodies Against Claudin 18.2
US	24.11.2006	15/710252	Monoclonal Antibodies Against Claudin-18 For Treatment Of Cancer
US	13.04.2016	15/565306	Methods and Compositions for Prediction of Therapeutic Efficacy of Cancer Treatments and Cancer Prognosis
US	21.05.2013	14/401899	Synopsis zu IMAB362 Kombinaltonsstudie "Gastchemo"
US	17.03.2014	14/777231	THERAPY INVOLVING ANTIBODIES AGAINST CLAUDIN 18.2 FOR TREATMENT OF CANCER
US	21.05.2013	15/231185	Combination Therapy Involving Antibodies Against Claudin 18.2 For Treatment of Cancer
US	24.11.2006	14/661846	Monoclonal Antibodies Against Claudin-18 For Treatment Of Cancer
US	18.05.2005	15/448831	Genetic Products Differentially Expressed In Tumors And The Use Thereof
US		16/037759	

Appendix-1